6533b853fe1ef96bd12ad6ab
RESEARCH PRODUCT
Through Predictive Personalized Medicine.
Pierangelo SardoGiuditta GambinoGiuseppe Gigliasubject
PD-L1medicine.medical_treatmentcomputational modellingHost factorsBioinformaticsSettore BIO/09 - Fisiologialcsh:RC321-57103 medical and health sciencesneuroblastoma0302 clinical medicineIntracellular signaling pathwaysSAFERMedicineSolid tumorlcsh:Neurosciences. Biological psychiatry. Neuropsychiatry030304 developmental biology0303 health sciencesbusiness.industryGeneral NeurosciencePediatric ageImmunotherapySurgical proceduresEditorial030220 oncology & carcinogenesisPersonalized medicineimmunotherapybusinessdescription
Neuroblastoma (NBM) is a deadly form of solid tumor mostly observed in the pediatric age. Although survival rates largely differ depending on host factors and tumor-related features, treatment for clinically aggressive forms of NBM remains challenging. Scientific advances are paving the way to improved and safer therapeutic protocols, and immunotherapy is quickly rising as a promising treatment that is potentially safer and complementary to traditionally adopted surgical procedures, chemotherapy and radiotherapy. Improving therapeutic outcomes requires new approaches to be explored and validated. In-silico predictive models based on analysis of a plethora of data have been proposed by Lombardo et al. as an innovative tool for more efficacious immunotherapy against NBM. In particular, knowledge gained on intracellular signaling pathways linked to the development of NBM was used to predict how the different phenotypes could be modulated to respond to anti-programmed cell death-ligand-1 (PD-L1)/programmed cell death-1 (PD-1) immunotherapy. Prediction or forecasting are important targets of artificial intelligence and machine learning. Hopefully, similar systems could provide a reliable opportunity for a more targeted approach in the near future.
year | journal | country | edition | language |
---|---|---|---|---|
2020-08-28 | Brain sciences |